Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan;13(1):108-117.
doi: 10.1111/luts.12341. Epub 2020 Aug 25.

A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

Yao-Chi Chuang  1 , Chih-Chieh Lin  2 , Po-Ming Chow  3 , Chi-Shun Lien  4 , Ke-Hung Tsui  5 , Chieh-Lung Chou  4 , Hsiang-Ying Lee  6 , En Meng  7 , Hann-Chorng Kuo  8
Affiliations
Randomized Controlled Trial

A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

Yao-Chi Chuang et al. Low Urin Tract Symptoms. 2021 Jan.

Abstract

Objective: This study evaluated the efficacy and safety of imidafenacin 0.1 mg twice daily vs placebo for Taiwanese patients with overactive bladder (OAB) after a 12-week oral administration.

Methods: This randomized, double-blind, placebo-controlled, two-arm, parallel-group, prospective study enrolled 118 patients across 11 study sites in Taiwan. Subjects were randomized to imidafenacin or placebo in a 2:1 ratio and entered the 12-week treatment period. At the subsequent visits, efficacy outcome measures and safety assessments were collected for analysis. The primary efficacy outcome was the change in the mean number of micturitions per day. Secondary endpoints included mean changes from baseline in urgency episodes and urge incontinence episodes per day and mean volume voided per micturition. Safety outcomes were also collected and compared between groups.

Results: A total of 78 and 40 patients were allocated to the imidafenacin and placebo groups, respectively. Among them, 100 patients (imidafenacin, 65 and placebo, 35) completed the trial. Compared with placebo, imidafenacin was significantly better at reducing the number of micturitions per day (-1.29 ± 2.23 vs -0.46 ± 3.49, P = .0171) and reducing the mean number of urge incontinence episodes (-0.15 ± 0.52 vs 0.04 ± 0.50, P = .0386) at week 12. Adverse events were reported in 35 subjects (44.9%) and 16 (40%) in the imidafenacin and placebo groups, including constipation (n = 3, 4), dry mouth (n = 11, 2), and urinary tract infection (n = 7, 4), respectively. One patient in the imidafenacin group had mild dysuria.

Conclusion: Imidafenacin demonstrated efficacy and safety in the treatment of OAB in Taiwanese patients.

Keywords: adverse events; antimuscarinics; overactive bladder; pharmacotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Meng En LWY, Lee WC, Chuang YC. Pathophysiology of overactive bladder. Low Urin Tract Symptoms. 2012;4(Suppl 1):48-55.
    1. Burgio KL. Current perspectives on management of urgency using bladder and behavioral training. J Am Acad Nurse Pract. 2004;16(Suppl 10):4-7.
    1. Arnold J, McLeod N, Thani-Gasalam R, Rashid P. Overactive bladder syndrome - management and treatment options. Aust Fam Physician. 2012;41:878-883.
    1. Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology. 2009;83:259-269.
    1. Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol. 2011;2011:820816.

Publication types

LinkOut - more resources